Safety Considerations and Who Should Seek Provider Evaluation First Patients with pre-existing kidney disease, liver dysfunction, or history of pancreatitis should not begin either semaglutide or glutathione supplementation without thorough medical evaluation
Longevity right now feels like the Wild West
In this case, the intermolecular interactions are similar in strength in the mixed and unmixed states, so the increase in entropy causes the substances to mix
Orforglipron is an oral non-peptide GLP-1 agonist that could solve the injection barrier entirely
Safety: what we know, what we dont What clinical trial safety reviews suggest The clinical safety review literature reports several reassuring signals: No meaningful increase in IGF-1 in monitored long-term studies (jofem.org) No clear negative effect on carbohydrate metabolism in testing described (contrast with full hGH) (jofem.org) No clear immunogenicity signal (e.g., anti-AOD antibodies) in the subset assessed in those trials (jofem.org) The major limitation: long-term real-world certainty is thin The problem with many peptides is not that everything is dangerousits that the certainty level is often lower than patients assume
260 Met metabolism regulates Cys and endogenous hydrogen sulfide (H 2 S) levels
